Acumen Pharmaceuticals Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“In order to understand the effects of ACU193 in intact animals, we performed behavioral studies in transgenic mice with genetic alterations that overproduce a mutant amyloid precursor protein that forms amyloid plaques.” (Page 116) Read the full document
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer’s disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients.
Company Website: https://acumenpharm.com